DK3680000T3 - Fremgangsmåder til oprensning af antistoffer - Google Patents

Fremgangsmåder til oprensning af antistoffer Download PDF

Info

Publication number
DK3680000T3
DK3680000T3 DK19198005.1T DK19198005T DK3680000T3 DK 3680000 T3 DK3680000 T3 DK 3680000T3 DK 19198005 T DK19198005 T DK 19198005T DK 3680000 T3 DK3680000 T3 DK 3680000T3
Authority
DK
Denmark
Prior art keywords
antibodies
purification
methods
Prior art date
Application number
DK19198005.1T
Other languages
Danish (da)
English (en)
Inventor
Kent E Goklen
Eric J Suda
Antonio Raul Ubiera
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3680000(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Application granted granted Critical
Publication of DK3680000T3 publication Critical patent/DK3680000T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • B01D15/3809Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK19198005.1T 2013-03-15 2014-03-13 Fremgangsmåder til oprensning af antistoffer DK3680000T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361787309P 2013-03-15 2013-03-15
EP14713926.5A EP2969098B1 (en) 2013-03-15 2014-03-13 Methods for purifying antibodies

Publications (1)

Publication Number Publication Date
DK3680000T3 true DK3680000T3 (da) 2024-04-02

Family

ID=50391244

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19198005.1T DK3680000T3 (da) 2013-03-15 2014-03-13 Fremgangsmåder til oprensning af antistoffer
DK14713926.5T DK2969098T3 (da) 2013-03-15 2014-03-13 Fremgangsmåder til oprensning af antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14713926.5T DK2969098T3 (da) 2013-03-15 2014-03-13 Fremgangsmåder til oprensning af antistoffer

Country Status (15)

Country Link
US (3) US10676503B2 (https=)
EP (3) EP2969098B1 (https=)
JP (2) JP6599773B2 (https=)
KR (1) KR102114021B1 (https=)
CN (1) CN105188872B (https=)
AU (1) AU2014229280B2 (https=)
BR (1) BR112015022321A2 (https=)
CA (1) CA2902287A1 (https=)
DK (2) DK3680000T3 (https=)
ES (2) ES2765206T3 (https=)
IL (1) IL240753B (https=)
RU (1) RU2651483C2 (https=)
SG (1) SG11201506494XA (https=)
TW (1) TWI625335B (https=)
WO (1) WO2014141150A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2969098B1 (en) 2013-03-15 2019-10-30 Glaxosmithkline Intellectual Property (No. 2) Limited Methods for purifying antibodies
EP2997036B1 (en) 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
US20170044210A1 (en) 2014-04-30 2017-02-16 Novo Nordisk A/S Methods for the purification of proteins using caprylic acid
CN108064286A (zh) 2015-01-26 2018-05-22 株式会社钟化 突变型免疫球蛋白κ链可变区结合性肽
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
WO2017195638A1 (ja) * 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
RU2759909C2 (ru) * 2016-09-07 2021-11-18 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы очистки антител
CN106939045B (zh) * 2017-05-01 2020-03-31 深圳市国创纳米抗体技术有限公司 一种单克隆抗体细胞培养液澄清的方法
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
TW202000891A (zh) 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
US20230302381A1 (en) * 2020-08-18 2023-09-28 Sartorius Bia Separations D.O.O. Metal-affinity extraction of host cell dna
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN116179582A (zh) * 2022-09-27 2023-05-30 南京医事达生物科技有限公司 一种通用型基因重组蛋白质a亲和纯化填料制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
DE60203176T2 (de) * 2001-06-01 2006-04-27 Upfront Chromatography A/S, Kopenhagen Fraktionierung von proteinhaltigen mischungen
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
MXPA04011769A (es) 2002-05-31 2005-07-26 Indian Agricultural Council Deteccion rapida de toxinas cry de bacillus thuringiensis.
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
WO2005113604A2 (en) * 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
WO2007109163A2 (en) * 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
CN101511387A (zh) 2006-09-08 2009-08-19 惠氏公司 使用亲和色谱法纯化蛋白质的精氨酸洗涤液
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
CN107915769A (zh) * 2011-03-29 2018-04-17 葛兰素史密斯克莱有限责任公司 用于蛋白纯化的缓冲液体系
EP2969098B1 (en) * 2013-03-15 2019-10-30 Glaxosmithkline Intellectual Property (No. 2) Limited Methods for purifying antibodies
EP2997036B1 (en) * 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物

Also Published As

Publication number Publication date
JP2016519052A (ja) 2016-06-30
KR102114021B1 (ko) 2020-05-22
US10676503B2 (en) 2020-06-09
CN105188872B (zh) 2019-01-15
EP2969098B1 (en) 2019-10-30
JP6599773B2 (ja) 2019-10-30
WO2014141150A1 (en) 2014-09-18
BR112015022321A2 (pt) 2017-07-18
CN105188872A (zh) 2015-12-23
EP4371996A2 (en) 2024-05-22
EP4371996A3 (en) 2024-08-14
US20200277330A1 (en) 2020-09-03
IL240753B (en) 2021-01-31
US12358945B2 (en) 2025-07-15
DK2969098T3 (da) 2020-01-27
US20250353878A1 (en) 2025-11-20
CA2902287A1 (en) 2014-09-18
US20160024146A1 (en) 2016-01-28
IL240753A0 (en) 2015-10-29
EP3680000A1 (en) 2020-07-15
RU2651483C2 (ru) 2018-04-19
RU2015136860A (ru) 2017-04-28
EP3680000B1 (en) 2024-03-13
TW201522365A (zh) 2015-06-16
JP2020019795A (ja) 2020-02-06
AU2014229280A1 (en) 2015-10-01
KR20150131235A (ko) 2015-11-24
AU2014229280B2 (en) 2017-01-05
TWI625335B (zh) 2018-06-01
ES2978309T3 (es) 2024-09-10
JP7002511B2 (ja) 2022-02-21
EP2969098A1 (en) 2016-01-20
SG11201506494XA (en) 2015-09-29
ES2765206T3 (es) 2020-06-08

Similar Documents

Publication Publication Date Title
DK3301115T3 (da) Kontinuerlig flertrinsfremgangsmåde til oprensning af antistoffer
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK3268390T3 (da) Fremgangsmåder til oprensning af bispecifikke antistoffer
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3113858T3 (da) Fremgangsmåde til oprensning af il-15/il-15ralpha-baserede konjugater
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
IL243311A0 (en) Novel antibody frameworks
DK3736291T5 (da) Anti-FCRH5-antistoffer
DK3134506T4 (da) Fremgangsmåder til oprensning af messenger rna
DK2970954T3 (da) Modifikation af polypeptider
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3006568T3 (da) Fremgangsmåde til fremstilling af tagatose
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3454346T3 (da) Anordning til cylotronfremstilling af technetium-99m
CL2016001519A1 (es) Anticuerpos anti-tau(ps422) humanizados y métodos de utilización
DK2961388T3 (da) Kombinationer af lægemidler
DK3010352T3 (da) Fremgangsmåde til fremstilling af fodertilsætning
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK2962754T3 (da) Fremgangsmåde til fremstilling af co-shiftkatalysator
DK3068800T3 (da) FcRn-specifikke antistoffer
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3510042T3 (da) Fremgangsmåde til rensning af antistoffer